Clinical trials: Neoplasms, Germ Cell and Embryonal
Uveal Melanoma
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
Neoadjuvant RBP-01 in patients with primary uveal melanoma.
- Trial name
- Uveal Melanoma (NCT07747935)
- Testing
- RBP-01
- Volunteers
- 30 people
- Sponsor
- ReBio Pharma
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Melanoma
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available.
- Trial name
- NCT00431275
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Melanoma
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
This is an expanded access program for eligible participants and is designed to provide access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients who previously participated in the 408-C-1401…
- Trial name
- NCT03593499
- Testing
- omaveloxolone
- Sponsor
- Biogen
Malignant Melanoma
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
This study was conducted to compare survival using pembrolizumab (SCH 900475, MK-3475) or standard chemotherapy in participants with advanced melanoma (MEL) who had progressed after prior therapy.
- Trial name
- NCT01704287
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroendocrine Tumors
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
- Trial name
- NCT02267967
- Testing
- Sulfatinib
- Where
- 7 sites in China
- Volunteers
- 81 people
- Sponsor
- Hutchison Medipharma Limited
Melanoma
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
- Trial name
- MAVIS (NCT01546571)
- Testing
- POL-103A, POL-103A without API
- Where
- 65 sites in United States, Canada
- Volunteers
- 504 people
- Sponsor
- Polynoma LLC
Metastatic Melanoma
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
This is a global, Phase 2, open label, dose selection, proof-of-concept study to assess progression free survival in subjects with metastatic melanoma.
- Trial name
- NCT01335009
- Testing
- MORAb-004 (monoclonal antibody)
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- Eisai Inc.
Melanoma, Head and Neck Squamous Cell Carcinoma
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
- Trial name
- AVENTIL (NCT05222932)
- Testing
- TILT-123, Avelumab
- Where
- 2 sites in United States, Finland
- Volunteers
- 15 people
- Sponsor
- TILT Biotherapeutics Ltd.
Metastatic Melanoma
Dose Escalation Study of MLN4924 in Adults With Melanoma
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor…
- Trial name
- NCT01011530
- Testing
- MLN4924
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Glioblastoma
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.
- Trial name
- NCT03152708
- Volunteers
- 62 people
- Sponsor
- CANbridge Life Sciences Ltd.
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Glioblastoma
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
- Trial name
- NCT02718443
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Vaximm GmbH
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Glioblastoma Multiforme
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
This study seeks to (i) determine the safe dose of CYT997 when given in combination with carboplatin in patients with relapsed glioblastoma multiforme (glioma) and (ii) to determine whether the combination of CYT997 with…
- Trial name
- NCT00650949
- Testing
- CYT997, Carboplatin
- Where
- 4 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company